Hormone Therapy News

The FDA approved a combination drospirenone and estetrol tablet for the prevention of pregnancy, the first combination pill containing naturally occurring estrogen, according to an industry press release.

Gender-affirming hormone therapy may cause a decrease in mean systolic BP in transgender women and an increase in mean systolic BP in transgender men, researchers reported.

Transgender adolescents treated with gender-affirming hormone therapy early in puberty experience bone development more similar to that of their experienced gender compared with their gender assigned at birth, according to study data.

Telemedicine visits for gender-affirming care in minors rapidly increased during the COVID-19 pandemic and may be able to expand access to care in the future, according to data from two studies published in Transgender Health.

Oral testosterone undecanoate is an effective long-term therapy for men with hypogonadism, with a safety profile that is similar to other approved testosterone formulations, data from an extension study show.

Arkansas on Tuesday became the first state to outlaw any gender-affirming medical treatments for minors who may be transgender, overriding a veto from the governor and prompting outcry from providers and advocates.

Subcutaneous testosterone was effective in allowing transgender male and gender-diverse youths to reach recommended testosterone levels and stop menses, with few severe adverse events, according to findings published in Transgender Health.

Children with a common form of skeletal dysplasia saw persistent and sustained improvements in annualized growth velocity with an investigational analogue of C-type natriuretic peptide, according to new data from an extension study.

Author of the Endocrine Society’s Clinical Practice Guideline on testosterone therapy for hypogonadism, Frances J. Hayes, MD, MBBCh, is nationally recognized for her expertise in testosterone deficiency.

Men who formerly used anabolic androgenic steroids have decreased levels of serum insulin-like factor 3, a marker for measuring Leydig cell function, according to data presented at the Endocrine Society Annual Meeting.